Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys, Tripos, Cerno Bioscience, Rosetta Biosoftware

Accelrys to Close Bangalore R&D Facility, Lay Off 60 Employees
Accelrys said this week in a filing with the US Securities and Exchange Commission that it will close an R&D facility in Bangalore, India, that it opened in 2003 [BioInform 05-12-03].
Accelrys said in the filing that the closure is in line with the “substantial completion” of its efforts to “modernize its legacy products.”
Accelrys said it will lay off 60 employees who work at the facility and that it will incur between $700,000 and $900,000 in severance and closure costs.
The company expects to complete the restructuring by the fourth quarter of its 2007 fiscal year, which ends March 31.
Accelrys laid off 50 staffers from its Cambridge, UK, and San Diego, Calif., facilities last March [BioInform 03-10-06].

Tripos Signs Agreement to Sell Discovery Research Group for $2M
Tripos said this week that it has signed an agreement to sell its UK-based Discovery Research business to Provid Pharmaceuticals in a stock sale worth roughly $2 million.
Tripos noted that the selling price could change, depending on changes in capital, debts, equipment, and facility values. The deal also hinges on Provid’s ability to secure the necessary financing.
The proposed sale would continue Tripos' plans to liquidate its assets and allow its Discovery Informatics and Discovery Research businesses to operate as private entities under other ownership in order to “maximize their potential for future success,” Tripos President and CEO John McAlister said in a statement.
McAlister said the Discovery Research group will maintain its base in Bude, UK, and said that Provid of North Brunswick, NJ, plans to retain the unit’s current management and staff.
The agreement follows the company’s announcement in November that it would sell its Discovery Informatics business to Vector Capital, a San Francisco-based private equity firm, for $26.5 million [BioInform 11-27-06].   
Tripos said at the time that it expects the Discovery Informatics acquisition to close in the first quarter of 2007.

Lumiere Technology to Distribute Cerno’s MassWorks in China
Cerno Bioscience said this week that it has signed an agreement with Lumiere Technology under which Lumiere will distribute Cerno’s MassWorks mass spectrometry analysis software in China.
Lumiere Technology is based in Beijing with offices in Shanghai, Shenyang, and Xi’an. The company also distributes Thermo Fisher Scientific’s mass spec product line in China.
According to Cerno, single- and triple-quadrupole mass specs are growing at a rate of 15 percent annually in China. The company claimed that its software can improve the mass accuracy of these systems by up to 100 times.

Eisai Licenses Rosetta’s Elucidator
Rosetta Biosoftware said this week that Japan’s Eisai has licensed its Elucidator software for differential protein expression analysis and biomarker discovery.
Eisai’s Laboratory of Seeds Finding Technology will use the software to identify potential neurology biomarkers, Rosetta said.
Financial terms of the agreement were not provided.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.